Article Text
PDF
Abstract
Objectives The purpose of this study was to systematically summarise the empirical evidence on the prevalence of HIV among long-distance truck drivers (LDTDs) from all parts of the world.
Design A systematic review and meta-analysis were conducted.
Data sources We searched PubMed, ProQuest Central, PubMed Central, Cumulated Index to Nursing and Allied Health Literature and Global Index Medicus to identify relevant information published from 1989 to 16 May 2023.
Eligibility criteria Peer-reviewed publications of English language reporting on the prevalence of HIV among LDTDs were included. Non-empirical studies like literature reviews were excluded.
Data extraction and synthesis Using a standardised data abstraction form, we extracted information on study characteristics and HIV prevalence levels. Crude prevalence estimates per 100 participants were computed and later transformed using logit transformation to have them follow a normal distribution. A meta-analysis of prevalences using the random effects model was performed. The I2 statistic was used to quantify the degree of heterogeneity across studies. A subgroup analysis using meta-regression was performed to investigate factors that could explain variability across studies. The Joanna Briggs Institute tools and Newcastle-Ottawa Scale were used to assess the quality of the included studies. To assess the certainty of evidence, the Grading of Recommendations Assessment, Development, and Evaluation approach was used.
Results Of the 1787 articles identified, 42 were included. Most of the included studies were conducted in sub-Saharan Africa (45.23%, n=19) and Asia and the Pacific (35.71%, n=15). The pooled prevalence of HIV was 3.86%, 95% CI (2.22% to 6.64%). The burden of HIV was highest in sub-Saharan Africa at 14.34%, 95% CI (9.94% to 20.26%), followed by Asia and the Pacific at 2.12%, 95 CI (0.94% to 4.7%) and lastly Western, Central Europe and North America at 0.17%, 95% CI (0.03% to 0.82%). The overall heterogeneity score was (I2=98.2%, p<0.001).
Conclusion The global burden of HIV among LDTDs is 3.86%, six times higher than that of the general population globally. Compared with other regions, the burden of HIV is highest in sub-Saharan Africa at 14.34%, where it is estimated to be 3% in the general population. Thus, LDTDs endure a disproportionately high burden of HIV compared with other populations. Consequently, more LDTD-centred HIV research and surveillance is needed at national and regional levels to institute tailored preventive policies and interventions.
PROSPERO registration number CRD42023429390.
- systematic review
- meta-analysis
- HIV & AIDS
- epidemiology
- infectious diseases
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
STRENGTHS AND LIMITATIONS OF THIS STUDY
The comprehensive search done across five databases minimised the risk of missing relevant studies in the systematic review and meta-analysis.
The selection of empirical peer-reviewed publications ensured that only primary data were used in the systematic review and meta-analysis, avoiding the bias of including secondary data from non-empirical studies.
A subgroup analysis enabled the researchers to get an understanding of some of the factors likely to explain variability across studies.
The searches were only done in the English language, meaning that data published in other languages may have been missed.
We observed some methodological limitations like the non-existence of data or small sample sizes in some regions which may limit the generalisability of the study findings to some parts of the world.
Introduction
Globally, the incidence rate of HIV has declined by 38%, from 2.1 million new infections in 2010 to 1.3 million new infections in 2022.1 While significant declines as high as 57% have occurred in Eastern and Southern Africa, the incidence rate of HIV has increased by 61% in the Middle East and North Africa and 49% in Eastern Europe and Central Asia.1 The declines point to key milestones that have so far been made in the control and prevention of HIV/AIDS; however, the increasing incidence rates in some parts of the world may derail the global efforts to end the epidemic.1 Moreover, the declines may mask the disproportionately high burden of HIV endured among certain key population groups like female sex workers (FSWs)2 and the hard-to-reach populations like the long-distance truck drivers (LDTDs).3 4
Studies have identified several factors likely to drive a high burden of HIV among LDTDs including sexual risk behaviours like poor condom use,5–8 multiple sexual partners,9–11 illicit drug and alcohol use during or before sexual interactions10 12–14 and risky sexual networks.15–18 Notably, LDTDs’ stopovers along their transit routes are characterised by prevalent commercial sex from FSWs whose risk of HIV infection is also high.19 Indeed, according to Joint United Nations Programme on HIV/AIDS (UNAIDS), FSWs were 30 times more likely to contract HIV in 2021, positioning their sexual clients like LDTDs at a high risk of contracting and spreading the infection.20 The LDTDs’ stopovers often lack proper HIV prevention measures, such as access to condoms, information and HIV testing services, further exacerbating the risk of transmission.21 Additionally, mental exhaustion and psychosocial problems due to long working hours while in transit have been implicated as predictors of risky sexual behaviours which likely elevate the burden of HIV among LDTDs.22–25 Moreover, LDTDs’ varying eligibility for HIV preventive services across different geographic borders,26 constant mobility27 28 and missed clinic appointments21 24 29 limit their access to essential preventive services, further predisposing them to the risk of HIV.
The burden of HIV among LDTDs has far-reaching health implications. In addition to the negative health outcomes for the drivers themselves, their frequent contact with other individuals, including their partners, FSWs and other populations along transit routes, increases the risk of HIV transmission to the general population. Unlike other high-risk groups like FSWs, there has been a paucity of information on the burden of HIV among the LDTDs at global, regional and national levels.
Hitherto, no systematic review has been done to quantify the global burden of HIV among LDTDs. Previous reviews have summarised the prevalence of HIV among LDTDs at national levels in Ethiopia30 and China,31 limiting the generalisability of their findings to other global settings. Therefore, with the increasing efforts to fight HIV, especially among the most at-risk populations, an extensive review is warranted to put into perspective the global burden of HIV among LDTDs. To address the aforementioned gap, this study set out to systematically summarise and analyse the available evidence on HIV prevalence among LDTDs from various parts of the world.
A review of this kind may amplify the evidence needed to guide surveillance and allocation of preventive resources, strategies and policies to reduce the burden of HIV among LDTDs in various parts of the world. More specifically, this review contributes to achieving the UNAIDS 95-95-95 targets by the year 2025 and the global goal to end AIDS by 2030.1 20
Methods
Protocol and registration
A protocol for this study was developed and registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD42023429390. The study followed the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines.32 A PRISMA checklist is provided in online supplemental table 1.
Supplemental material
Eligibility criteria
Articles identified from the electronic search had to meet predetermined inclusion and exclusion criteria to be included. The inclusion and exclusion criteria were categorised into condition (HIV), context (where the studies were conducted), population of interest (LDTDs) and the study design. A summary of the inclusion and exclusion criteria is provided in table 1.
Inclusion and exclusion criteria for selected studies
Information sources
A comprehensive structured electronic search was conducted in PubMed, PubMed Central (PMC), Cumulated Index to Nursing and Allied Health Literature (CINAHL), ProQuest Central and Global Index Medicus to identify all relevant studies published since inception to 16 May 2023 (when the last search was conducted). Additional studies were manually searched from the list of references available from the full-text articles retrieved.
Search strategy
The basic search terms were divided into three categories: (1) condition (HIV OR AIDS OR HIV/AIDS OR Sexually transmitted diseases); (2) population (Long-distance truck drivers OR Long-distance truckers OR Long-haul truck drivers); and (3) outcome measures (prevalence OR burden OR risk). Synonyms in each of the search categories were combined with the Boolean operator ‘OR’. The three search categories were combined with the Boolean operator ‘AND’ to form the following search string (HIV OR AIDS OR HIV/AIDS OR ‘Human immunodeficiency virus’ OR ‘Immune suppression’ OR ‘Immuno-suppression’ OR ‘Acquired immune deficiency syndrome’ OR ‘sexually transmitted diseases’ OR ‘sexually transmitted infections’ OR ‘venereal diseases’ OR ‘venereal infections’) AND (prevalence OR burden OR proportion OR epidemiology OR frequency OR risk) AND (Truckers OR ‘Long-distance truckers’ OR ‘Long-distance truck drivers’ OR ‘Long-haul drivers’ OR ‘Long-haul truck drivers’ OR ‘Long-haul truck assistants’ OR ‘Long-distance truck assistants’ OR ‘Migrant truck drivers’ OR ‘Migrant truck assistants’). Medical subject headings were also used where applicable. Where the search was unsuitable for a database, it was modified accordingly. All searches were restricted to studies published in English. Search strings from PubMed and PMC databases are provided in online supplemental file 1.
Supplemental material
Selection process
Two reviewers, CM and BO, independently screened the records for eligibility in three stages. In the first stage, deduplication was done using the Zotero bibliography software. This was followed by the screening of titles and abstracts using the Rayyan online platform.33 In the third stage, full-text articles were assessed for eligibility. Ineligible studies were removed, and their bibliographic details were listed with specific reasons. Any disagreements between the two reviewers were resolved by a third author GM.
Data extraction and data items
Using a standardised Microsoft Excel data extraction form, CM independently extracted the following variables from the retrieved articles: (1) details of the retrieved articles (author and year of publication); (2) details of the study (year the study was conducted, country, continent, region, economic class of the country of origin, community or hospital based and study design); (3) characteristics of study participants (sample size, gender and age); and (4) measures of outcome (laboratory method used to diagnose HIV, number of HIV positives, HIV prevalence, levels of HIV infection compared with the general population, predicting factors and quality scores). Thereafter, BO went through the extracted data, flagged possible anomalies and resolved them through a consensus with CM. These variables were coded appropriately in an Excel spreadsheet, to enable ease in data synthesis and analysis.
Risk of bias and quality assessment
Two reviewers, CM and BO, independently assessed the risk of bias and quality for each study. This was done using the Joanna Briggs Institute (JBI) critical appraisal tools34 35 for cross-sectional (prevalence) studies and non-randomised interventional (quasi-experimental) studies and the Newcastle-Ottawa Scale (NOS) for assessing the quality and bias of cohort studies.36 The quality of the prevalence studies was graded based on nine items in the JBI checklist. Following the NOS recommendations, the grading of the cohort studies was based on stars and categorised as follows: 0–4: unsatisfactory; 5–6: satisfactory; 7–8: good; and 9–10: very good. Additionally, publication bias was assessed using funnel plots (figure 3)37 and Luis Furuya-Kanamori (LFK) index and Doi plot (figure 4)38 39. Asymmetry in the funnel plot points to a possibility of publication bias. However, for a more certain assessment of publication bias, LFK index and Doi plots are recommended.37–39 An LFK index which is outside negative one (−1) and positive one (1) intervals indicates the presence of publication bias in the included studies. Asymmetry of the Doi plot has been suggested to have more compelling evidence of publication bias than funnel plots.37–39
Strategy for data synthesis
The reviewers derived individual study proportions by dividing the number of HIV-positive cases reported by the size of the sample studied and then computed the overall crude prevalence estimates expressed per 100 participants, for the positive cases stratified according to age and study region among other potential correlates. To obtain a more precise estimate of the overall prevalence of HIV and to assess for heterogeneity across studies, a meta-analysis of prevalences using the random effects model was performed using R V.4.3.1.40 More specifically, the ‘meta’ package in R statistical software was used.41 The researchers transformed reported prevalences using logit transformation to have them follow a normal distribution, hence ensuring an accurate estimate of the summary prevalences, where the logit transformation of the prevalence and its inverse variance weight were calculated as ln (p/1−p) and wl=np (1−p), respectively.42 While there are other methods to transform the prevalence estimates like the Freeman-Tukey double arcsine transformation, the authors used the logit transformation for it is more suitable for the assumptions of normality between studies and can take any real values.43
After the analysis, the transformed prevalence and the CIs were back-transformed to prevalence for reporting. A formal χ2 test with a Q-statistic was used to assess for study heterogeneity under a null hypothesis of homogeneity among the study effect sizes,44 as heterogeneity could result from study sampling error or between studies’ variability due to true effect size differences across reported studies. Also, because of the variation in methodological approaches, sample sizes and the study settings, heterogeneity was anticipated. The researchers applied a random effects model to quantify the degree of heterogeneity using the I2 statistic, where it was assumed that I2 values of 25%, 50% and 75% indicate low, moderate and high heterogeneity, respectively, as the values of I2 increase with increasing levels of heterogeneity.45 Forest plot was used to visualise the heterogeneity among studies, prevalence estimates and their CIs. Visual inspection of the degree of asymmetry was done using funnel plots to assess potential publication bias. Further, univariable and multivariable meta-regression analyses were done to investigate factors attributable to heterogeneity.
Analysis of subgroups or subsets
The reviewers investigated potential factors that could explain the variability in prevalence estimates across the studies when I2 values are substantial using meta-regression univariable and multivariable models. This was performed using logit transformed proportions, individual effect sizes and their corresponding sampling variances. Factors such as year of study publication, the continent of the study, country income classification, study setting, age group, country of study, measurement tool used, sample size and quality score of the study were investigated to examine and quantify the magnitude of their impact on prevalence estimates. These factors were identified a priori as potential contributors to heterogeneity based on existing literature.
Certainty of evidence
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the certainty of evidence.46 Two reviewers, CM and BO, independently assessed the certainty of evidence in the included studies and graded them as either, high, moderate, low or very low quality. By default, observational studies were graded as low quality and upgraded if there were no plausible confounders or major threats to validity. For randomised trials, the default level of confidence was high quality but downgraded if there was a risk of bias, inconsistencies, indirectness, imprecision and publication bias.
Patients and public involvement
Patients and the public were not involved in this study.
Results
Study selection
The initial electronic search yielded a total of 1787 articles from five databases (PubMed, n=150; PMC, n=746; ProQuest Central, n=834; CINAHL, n=51, and Global Index Medicus, n=6). An additional 12 articles were identified from the reference list and Google Scholar. A total of 63 duplicates were removed, after which 1736 articles were screened for eligibility. Out of these, 1634 irrelevant records were excluded based on their title and abstract. After screening the remaining 102 full texts, 42 studies were included in the review and meta-analysis. A PRISMA flow chart for the systematic review process is shown in figure 1.
Preferred Reporting Items for Systematic Review and Meta-analysis flowchart. CINAHL, Cumulated Index to Nursing and Allied Health Literature; LDTDs, long-distance truck drivers.
Study characteristics
A detailed summary of the 42 included studies is provided in online supplemental table 2. Most of the included studies (64.29%, n=27), were published between 1989 and 2010, except for those (35.71%, n=15) published from 2011 and onwards. A majority of the included studies were conducted in sub-Saharan Africa (45.24%, n=19), followed by Asia and the Pacific (35.71%, n=15), with Eastern Europe and Central Asia trailing behind with only one study. Studies from sub-Saharan Africa were mostly conducted in Kenya (n=5) and South Africa (n=4), whereas in Asia and the Pacific, most of them were conducted in India (n=11). A map showing the geographical distribution of the studies is given in online supplemental figure 1. Almost all of the included studies (90.48%, n=38) were cross-sectional by design3 9 11 27 47–80 except for two prospective cohort studies81 82 and two non-randomised interventional studies.83 84
Supplemental material
Supplemental material
Study population
The 42 included studies comprised a total sample size of 34 658, ranging from 6856 to 376353 by individual studies. By region, the highest sample size was Asia and the Pacific (n=15 871, 45.54%) followed by sub-Saharan Africa (n=10 014, 28.74%). Only one included study conducted in New Mexico, USA,79 involved both male and female LDTDs, whereas the rest had predominantly male participants. Most of the included studies (79.07%, n=33) targeted LDTDs as the primary study population, except for studies51 63 64 68 71–73 81 82 which involved a mixture of LDTDs and other study populations (online supplemental table 2).
Laboratory method of HIV diagnosis
ELISA was widely used as the laboratory method of diagnosing HIV in most (74.42%, n=31) of the included studies, except for studies47 56 57 59 71 77 79 where a combination of ELISA and western blot assay technologies were used. Other individual studies used enzyme immunoassay and Innotest HIV-1/HIV-2,69 Orasure,3 Determine & OraQuick53 and OraQuick,50 as provided in online supplemental table 2.
HIV prevalence estimates
The pooled prevalence of HIV among LDTDs in all global regions was 3.86% (95% CI: 2.22% to 6.64%), as shown in table 2. In the subgroup analysis by region, the highest prevalence of HIV among LDTDs was from sub-Saharan Africa 14.34% (95% CI: 9.94% to 20.26%), followed by Asia and Pacific 2.12% (95% CI: 0.94% to 4.70%), Eastern Europe and Central Asia 1.54% (95% CI: 1.17% to 1.99%), Latin America and Caribbean 0.37% (95% CI: 0.08% to 1.60%), Middle East and North Africa 0.27% (95% CI: 0.08% to 0.93%) and lastly Western, Central Europe and North America registering the lowest estimates of 0.17% (95% CI: −0.03% to 0.82%). In sub-Saharan Africa, the highest prevalence rates (above 15%) were reported in South Africa,3 76 Uganda,56 Kenya,55 70 82 Burkina Faso67 and Cameroon.72 In the Asia and Pacific region, the highest HIV prevalence estimates were from India,11 60 63 69 74 whereas China registered the lowest prevalence rates.57 In Latin America and the Caribbean, the highest HIV prevalence estimates were from Brazil.65 In the other regions, there were no wide variations in the HIV prevalence reported from individual countries. Details of the pooled prevalence in the different studies are given in table 2. Forest plots showing more details of the subgroup analysis are shown in figure 2.
Forest plots.
Pooled prevalence and subgroup analysis of the burden of HIV among long-distance truck drivers
Heterogeneity of included studies
The overall heterogeneity score was (I2=98.2, p<0.001) indicating that the 42 studies included were highly heterogeneous. By regions, the highest heterogeneity was from studies conducted in sub-Saharan Africa (I2=97.0, p<0.01), followed by those from Asia and the Pacific (I2=97, p<0.01). Studies from the Middle East and North Africa, Eastern Europe and Central Asia and Western, Central Europe and North America had the lowest level of heterogeneity though not statistically significant as shown in online supplemental table 3 and figure 2. Further investigation revealed that the year of publication (aβ −0.04; 95% CI (−0.09 to −0.01); p=0.03) a study being conducted in the regions of sub-Saharan Africa (aβ 1.719; 95% CI (0.94 to 2.45); p<0.0001), Latin America and the Caribbean (aβ −1.89; 95% CI (−3.42 to −0.36); p=0.02) and Western, Central Europe and North America (aβ −2.43; 95% CI (−4.73 to −0.13); p=0.04) significantly accounted for heterogeneity in the included studies as given in online supplemental table 3.
Supplemental material
Bias and quality scores of the included studies
Of the 38 cross-sectional studies included, 11 were of high quality (low risk of bias),11 27 55 57 61 69 73–76 80 extra 9 were of good quality (low risk of bias),3 51–53 59 64 66 77 79 3 were of low quality (high risk of bias),9 67 70 whereas the remaining 15 had a fair rating (moderate risk of bias). All the cohort81 82 and interventional83 84 studies included were of high-quality rating (low risk of bias). The quality scores of the included cross-sectional, cohort and non-randomised interventional studies were generated and are provided in online supplemental tables 4–6. The generated funnel plot was asymmetrical implying the presence of publication bias in the included studies as indicated in figure 3. More specifically, publication bias was indicated by an LFK index of −6.35 which was outside the recommended (−1) and (1) interval and asymmetry of the Doi plot as shown in figure 4.
Supplemental material
Supplemental material
Supplemental material
Funnel plot.
Luis Furuya-Kanamori (LFK) index and Doi plot showing publication bias in the 42 included studies.
Certainty of evidence
The certainty of evidence for the 42 studies was graded as very low. Only one study83 was graded as of low quality. The quality of evidence was mainly influenced by the observational nature of most of the included studies. A detailed summary of the GRADE certainty of evidence assessment for all included studies is provided in online supplemental table 7.
Supplemental material
Discussion
This systematic review and meta-analysis summarised the global evidence of HIV among LDTDs. The findings from this study demonstrate substantial evidence of high levels of HIV across LDTDs of diverse geographical backgrounds such as sub-Saharan Africa, Asia and the Pacific. While for a long time, LDTDs were understood to be both most-at-risk5 6 9 13 15 17 19 85 and a hard-to-reach population,3 4 18 27 this is the pioneer study to systematically determine and report the extent of the burden of HIV in this key population.
The pooled prevalence of HIV was 3.86% (95% CI: 2.22% to 6.64%). This is nearly six times the current global HIV prevalence of 0.7% in the adult general population based on the latest UNAIDS report.1 This pooled prevalence is higher than those reported for other most-at-risk populations like sex workers (2.5%) and people in prisons (1.4%), but lower than that of people who inject drugs (5.0%), gay men and other men who have sex with men (7.7%) and transgender groups (10.3%).1 Moreover, the pooled prevalence was substantially higher compared with the prevalence of HIV in other migrant populations in high-income countries (2.25%) and low-income countries (0.23%).86 Nevertheless, a recent meta-analysis identified a prevalence of 17.3% among FSWs in the USA.87 This finding demonstrated that LDTDs endure a high burden of HIV especially in sub-Saharan Africa, Asia and the Pacific regions. However, this assertion may not suffice for some regions like Latin America and the Caribbean, Eastern Europe and Central Asia, Middle East and North Africa and Western, Central Europe and North America, where a very low number of studies were identified. Indeed, the high burden of HIV may for long have been masked by the greater attention given to other most-at-risk populations, somewhat neglecting LDTDs in various HIV preventive and research programmes owing to their hard-to-reach nature.88 Furthermore, the high burden may infer delayed success of HIV prevention among this population, which consequentially derail the collective global efforts to fight the epidemic. Therefore, there is a need to scale up targeted interventions with an emphasis on combination prevention, a holistic approach with effective structural, biomedical and behavioural HIV prevention services among LDTDs as recommended by the UNAIDS.20
In the current study, the highest pooled prevalence of HIV among LTDs was in sub-Saharan Africa, followed by the Asia and Pacific region and the least from Western, Central Europe and North America. This is so despite the sample size from sub-Saharan Africa (28.89 %), being nearly a third of that of the entire study. Thus, the high overall pooled prevalence observed is attributable to the sub-Saharan Africa region. This trend is consistent with the global burden of HIV in the general population which is highly concentrated in sub-Saharan Africa.1 20 Indeed, the 14.34% HIV prevalence which is about five times that of the general population estimated to be around 3% in the region.1 Moreover, a high burden of HIV among LDTDs was concentrated in the Eastern54–56 70 82 and Southern3 27 76 regions of sub-Saharan Africa, compared with the Western and Central Africa region, reflecting the UNAIDS report on HIV trends in the general population.1 20
The high burden of HIV among LDTDs in sub-Saharan Africa may be attributed to various factors. First, studies have identified that LDTDs in sub-Saharan Africa mainly solicit commercial sex from FSWs, who equally share a disproportionately high burden of HIV.19 76 89 Sexual interactions between LDTDs and commercial sex workers are known to be characterised by risky sexual behaviours,19 which increases the risk of HIV infection. Additionally, limited access and inadequate HIV preventive services among LDTDs along most transport routes in sub-Saharan Africa3 66 90 increase their vulnerability to HIV. Furthermore, due to limited healthcare resources in most sub-Saharan African countries, LDTDs may find themselves ineligible for HIV preventive services across different geographic borders.26 The high burden of HIV among LDTDs in sub-Saharan Africa may partially be a driving factor to the high burden sustained in the region. Thus, to sustain the currently reducing HIV incidence rates in sub-Saharan Africa, enhanced targeted HIV preventive services among the LDTDs are needed to match those offered in other most-at-risk populations like the FSWs.
The 2.12% prevalence of HIV among LDTDs in Asia and the Pacific is above the estimates of below 1% in the general population in the region.1 However, the prevalence reported by individual studies widely varied, with some studies from India reporting a prevalence of above 15%,60 63 69 compared with a prevalence of 0% in Bangladesh61 and China.57 Thus, this evidence also demonstrates the need for enhanced HIV preventive services among LDTDs in Asia and the Pacific.
There was a low number of studies identified from Latin America and the Caribbean, Western, Central Europe and North America, Middle East and North Africa and Eastern Europe and Central Asia, with each region having less than three studies. Ultimately, the data from these regions is inadequate to make a conclusive comparison in the context of the current study. This may be due to under-reporting of HIV prevalence or a lack of studies that focus on HIV among LDTDs in those regions. Indeed, given the relatively low burden of HIV in those regions,1 LDTD-centred research has been focused on other healthcare needs.12 50 91–94 However, this school of thought may not be completely true, given the recent sharp increase in incidence rates of HIV in some of the regions mentioned above like the Middle East, North Africa and Eastern Europe.1 Nevertheless, the HIV prevalence reported in the individual studies still demonstrates a substantial prevalence of HIV which needs intervention programmes. Moreover, LDTD-centred research and HIV surveillance activities are needed to guide the formulation of suitable targeted strategies, policies and interventions to prevent new infections.
This review identified an overall heterogeneity of 98.2%, p<0.001, in the included studies. This may partly be attributable to the year of publication and the different contexts from which the studies were conducted like sub-Saharan Africa, Latin America and the Caribbean and Western, Central Europe and North America.95 More specifically, most of the included HIV prevalence studies were published before 2010. Indeed, only two studies have been conducted in the last 5 years on HIV prevalence among LDTDs.52 77 This is an indication of a decelerating or stagnated body of evidence on HIV among LDTDs in different parts of the world. Such a scenario is likely to mask and drive a silent disproportionately high burden of HIV in this population. Thus, more studies and surveillance are needed in individual countries to generate reliable up-to-date HIV prevalence estimates for more appropriate targeted interventions.
Strengths and limitations
This is the first study to systematically summarise and analyse the global burden of HIV among LDTDs. Despite LDTDs being at higher risk of HIV from various global settings, evidence of this kind did not exist before. Therefore, the HIV prevalence estimates identified in this study will inform resource allocation and HIV prevention interventions targeted for LDTDs across various parts of the world.
Several limitations should be considered when interpreting the findings of this review. First, the review included all existing studies on HIV prevalence among LDTDs since the start of the epidemic. Thus, a portion of the data may not be up to date. However, given the lack of any existing review of this kind, the current study was warranted. Second, the review focused on studies only published in the English language, meaning that some data published in other languages may have been left out, thus possibly underestimating or overestimating the global burden of HIV among LDTDs. The high heterogeneity in the included studies may limit the generalisability of the findings especially from regions where there was a huge scarcity of data. The diversity of study settings, year of publication, sample size and socioeconomic factors among the study sample may also limit the generalisability of the findings. Moreover, it is important to note that the pooled prevalence reported in this study includes data from studies published more than a decade ago. This may not be an accurate reflection of the current situation. Therefore, comparing the pooled prevalence with the current global prevalence of HIV may have its limitations. Lastly, some databases that are not open access were not searched for the information included in the current study. It may be that some important information in those databases was left out in this review.
Conclusion
The global burden of HIV among LDTDs is 3.86%. This burden is highest in sub-Saharan Africa at 14.34%, followed by Asia and the Pacific at 2.12% and the lowest in Western, Central Europe and North America at 0.17%. More LDTD-centred research and surveillance on HIV prevalence is recommended in individual countries. This would be pivotal in instituting tailored national and regional strategies, policies and interventions suitable for preventing new HIV infections among LDTDs.
Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.
Ethics statements
Patient consent for publication
Ethics approval
Not applicable.
Acknowledgments
We acknowledge the Faculty of Nursing, Jomo Kenyatta University of Agriculture and Technology, for their input during the preliminary presentation of this study.
References
Supplementary materials
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Footnotes
Contributors CM, BO and GM conceptualised the study and design. CM and BO performed the literature searches, screening of titles and abstracts, data extraction, assessment of biases in the studies and formal analysis. GM supported in developing the main search string for the review. CM wrote the original draft. EM, KK, JG, AM and GM supervised the entire study process. All authors read, revised and approved the final version of the manuscript. CM is the guarantor and is responsible for the overall content.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.